{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T10:03:09Z","timestamp":1785578589934,"version":"3.56.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"29","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.vaccine.2016.05.025","type":"journal-article","created":{"date-parts":[[2016,5,18]],"date-time":"2016-05-18T01:33:42Z","timestamp":1463535222000},"page":"3331-3334","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Estimated prevalence of smallpox vaccine contraindications in Israeli adolescents"],"prefix":"10.1016","volume":"34","author":[{"given":"Itay","family":"Fogel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tal","family":"Brosh-Nissimov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Granit","family":"Vager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaron","family":"Aviv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kassirer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.05.025_bib0105","first-page":"71","article-title":"The elimination of smallpox from Israel","volume":"3","author":"Slater","year":"2001","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.vaccine.2016.05.025_bib0110","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1086\/423851","article-title":"Clinical and immune responses after revaccination of Israeli adults with the Lister strain of vaccinia virus","volume":"190","author":"Orr","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.05.025_bib0115","first-page":"1","article-title":"Smallpox vaccination and adverse reactions. Guidance for clinicians","volume":"52","author":"Cono","year":"2003","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2016.05.025_bib0120","first-page":"1","article-title":"Advisory Committee on Immunization Practices; Healthcare Infection Control Practices Advisory Committee. Recommendation for using smallpox vaccine in a preevent vaccination program","volume":"52","author":"Wharton","year":"2003","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2016.05.025_bib0125","first-page":"282","article-title":"Supplemental recommendations on adverse events following smallpox vaccine in the pre-event vaccination program: recommendations of the Advisory Committee on Immunization Practices","volume":"52","author":"Centers for Disease Control and Prevention (CDC)","year":"2003","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2016.05.025_bib0130","first-page":"1","article-title":"Clinical guidance for smallpox vaccine use in postevent vaccination program","volume":"64","author":"Petersen","year":"2015","journal-title":"MMWR Recomm Rep"},{"issue":"January","key":"10.1016\/j.vaccine.2016.05.025_bib0135","first-page":"39","volume":"1","author":"The Israel Ministry of Health","year":"2011","journal-title":"The doctrine for an outbreak of smallpox"},{"key":"10.1016\/j.vaccine.2016.05.025_bib0140","first-page":"84","article-title":"Expected adverse events in a mass smallpox vaccination campaign","volume":"5","author":"Kemper","year":"2002","journal-title":"Eff Clin Pract"},{"key":"10.1016\/j.vaccine.2016.05.025_bib0145","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.vaccine.2006.09.046","article-title":"An update on smallpox vaccine candidates and their role in bioterrorism related vaccination strategies","volume":"25","author":"Wiser","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.05.025_bib0150","doi-asserted-by":"crossref","first-page":"6632","DOI":"10.1016\/j.vaccine.2012.08.072","article-title":"Estimated size of the population at risk of severe adverse events after smallpox vaccination in Israel","volume":"30","author":"Levy","year":"2012","journal-title":"Vaccine"},{"issue":"Pt 5","key":"10.1016\/j.vaccine.2016.05.025_bib0155","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1099\/0022-1317-79-5-1159","article-title":"Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine","volume":"79","author":"Blanchard","year":"1998","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2016.05.025_bib0160","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.vaccine.2005.11.022","article-title":"Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine","volume":"24","author":"Vollmar","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.05.025_bib0165","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1128\/JVI.01706-07","article-title":"Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus ankara is comparable to that of Dryvax","volume":"82","author":"Davies","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.05.025_bib0170","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1136\/bmj.2.5414.906","article-title":"Eczema vaccinatum","volume":"2","author":"Copeman","year":"1964","journal-title":"Br Med J"},{"key":"10.1016\/j.vaccine.2016.05.025_bib0175","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jaci.2009.10.024","article-title":"Vaccinia virus-specific molecular signature in atopic dermatitis skin","volume":"125","author":"Grigoryev","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2016.05.025_bib0180","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1084\/jem.20082835","article-title":"Inhibition of NK cell activity by IL-17 allows vaccinia virus to induce severe skin lesions in a mouse model of eczema vaccinatum","volume":"206","author":"Kawakami","year":"2009","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2016.05.025_bib0185","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/milmed\/165.4.287","article-title":"Adverse reactions to smallpox vaccine: the Israel Defense Force experience, 1991 to 1996. A comparison with previous surveys","volume":"165","author":"Haim","year":"2000","journal-title":"Mil Med"},{"key":"10.1016\/j.vaccine.2016.05.025_bib0190","doi-asserted-by":"crossref","first-page":"658","DOI":"10.3928\/00904481-20100922-05","article-title":"Eczema herpeticum and eczema vaccinatum in children","volume":"39","author":"Jen","year":"2010","journal-title":"Pediatr Ann"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2016.05.025_bib0195","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000370220","article-title":"Atopic dermatitis: global epidemiology and risk factors","volume":"66","author":"Nutten","year":"2015","journal-title":"Ann Nutr Metab"},{"key":"10.1016\/j.vaccine.2016.05.025_bib0200","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/PHH.0b013e3182941a5a","article-title":"Geospatial analytics to evaluate point-of-dispensing sites for mass immunizations in Allegheny County, Pennsylvania","volume":"19","author":"Everett","year":"2013","journal-title":"J Public Health Manag Pract"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16303152?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16303152?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T15:47:32Z","timestamp":1567871252000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16303152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":20,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S0264410X16303152"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.05.025","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Estimated prevalence of smallpox vaccine contraindications in Israeli adolescents","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.05.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}